Human Mesenchymal Stem Cells Lack Tumor Tropism but Enhance the Antitumor Activity of Oncolytic Adenoviruses in Orthotopic Lung and Breast Tumors
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Systemic adenoviral delivery into tumors is inefficient because of liver sequestration of intravenously administered virus. One potential solution for improving bioavailability is the use of carrier cells such as human mesenchymal stem cells (MSCs), which have been suggested to have inherent tumor tropism. Here we investigated the capacity of capsid-modified adenoviruses to infect and replicate in MSCs. Further, biodistribution and tumor-killing efficacy of MSCs loaded with oncolytic adenoviruses were evaluated in orthotopic murine models of lung and breast cancer. In vitro, heparan sulfate proteoglycan- and alpha(v)beta integrin-targeted viruses enhanced gene delivery to bone marrow- and adipose tissue-derived MSCs up to 11,000-fold over adenovirus serotype 5 (Ad5). Infectivity-enhanced oncolytic adenoviruses showed notably higher rates of cytolysis of in vitro-passaged MSCs in comparison with wild-type virus. In vivo, intravenously injected MSCs homed primarily to the lungs, and virus was released into advanced orthotopic breast and lung tumors for therapeutic efficacy and increased survival. When the same dose of virus was injected intravenously without MSCs, only transduction of the liver was seen. These results suggest that MSCs loaded with oncolytic adenoviruses might be a useful approach for improving the bioavailability of systemically administered oncolytic adenoviruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 1×
“For example, deleting 24 bp from constant region 2 of E1A limits replication to cells in which the p16/Rb pathway is dysregulated, which includes the majority of human cancer cells (Sherr, 1996; Fueyo et al., 2000; Heise et al., 2000).”
BackgroundHuman mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511 · cited 3×
“logeneic rejection in humans and animal models, which broadens the potential for their therapeutic use (Le Blanc et al., 2004; Aggarwal and Pittenger, 2005).”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“It has been hypothesized that the tumor environment resembles injured tissue and therefore circulating MSCs would home into tumor tissue (Dvorak, 1986; Studeny et al., 2002, 2004).”
BackgroundKern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 1×
“In fact, it has been suggested that there might be similarities between adipose- and bone marrow-derived MSCs both on biological and molecular levels (Izadpanah et al., 2006; Kern et al., 2006; Talens-Visconti et al., 2006).”
BackgroundLe Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue
Izadpanah, R., Trygg, C., Patel, B., Kriedt, C., Dufour, J., Gimble, J. M., & Bunnell, B. A. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20904 · Cited by 670 · cited 1×
“In fact, it has been suggested that there might be similarities between adipose- and bone marrow-derived MSCs both on biological and molecular levels (Izadpanah et al., 2006; Kern et al., 2006; Talens-Visconti et al., 2006).”
BackgroundAntitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597 · cited 1×
“Modified MSCs have already been used preclinically as anticancer therapeutics for glioma, metastatic melanoma, and ovarian cancer (Studeny et al., 2002, 2004; Nakamura et al., 2004; Nakamizo et al., 2005; Komarova et al., 2006).”
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Komarova, S., Kawakami, Y., Stoff-Khalili, M. A., Curiel, D. T., & Pereboeva, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0334 · Cited by 302 · cited 5×
“In fact, studies have shown that genetically modified MSCs are capable of homing into tumors and show antineoplastic activity in vivo in xenograft murine glioma, melanoma, and ovarian and breast cancer models (Studeny et al., 2002, 2004; Nakamizo et al., 2005; Komarova et al., 2006).”
BackgroundInfluential
Cited by
Stem Cells and Cell Therapies in Lung Biology and Lung Diseases
Weiss, D. J., Kolls, J. K., Ortiz, L. A., Panoskaltsis-Mortari, A., & Prockop, D. J. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200804-037dw · Cited by 309
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles
Wong, H. H., Lemoine, N. R., & Wang, Y. (2010) · Viruses · doi:10.3390/v2010078 · Cited by 180
“Cells that have been tested include mesenchymal stem cells [157-159], monocytes [160], outgrowth endothelial cells [160], tumor cells [161-163], T cells [164-166], and dendritic cells (DCs) [165].”
BackgroundGenetic Engineering of Mesenchymal Stem Cells and Its Application in Human Disease Therapy
Hodgkinson, C. P., Gomez, J. A., Mirotsou, M., & Dzau, V. J. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.165 · Cited by 150
Stem cells as vectors for antitumour therapy
Loebinger, M. R., & Janes, S. M. (2010) · Thorax · doi:10.1136/thx.2009.128025 · Cited by 109
“This therapy improved survival in a murine ovarian cancer model, 14 orthotopic breast and lung tumour models, 55 and a lung metastasis model.”
BackgroundSlama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
The role of mesenchymal stem cells in oncology and regenerative medicine
Maliha, K., Syeda Ezze Rukhshan, A., & Amanda L, O. (2017) · Future Oncology · doi:10.2217/fon-2016-0264 · Cited by 5
Metadata
- Authors
- Hakkarainen, T., Särkioja, M., Lehenkari, P., Miettinen, S., Ylikomi, T., Suuronen, R., Desmond, R. A., Kanerva, A., & Hemminki, A.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2007-07
- Volume
- 18
- Issue
- 7
- Pages
- 627-641
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2002730346
- Cited by
- 146
- References
- 8
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.